Hospital wastewater is attracting greater attention as a source of pharmaceutical pollution and antimicrobial resistance. Most hospital effluent enters municipal wastewater systems, yet conventional treatment plants are not designed to remove pharmaceutical compounds, resistant bacteria or resistance genes effectively. As a result, residues can persist and enter the environment. Although households contribute more pharmaceutical residues overall, hospitals remain important hotspots because of their intensive use of substances such as antibiotics, cytostatics and contrast agents. European policy frameworks recognise the issue, but practical action remains constrained by limited guidance, funding and infrastructure.
Why Hospital Effluent Requires Dedicated Measures
Hospital wastewater differs significantly from community pharmaceutical pollution. It contains healthcare-specific compounds largely absent from domestic wastewater, including iodinated contrast agents used in diagnostic imaging. These substances are chemically stable and persist in aquatic environments. Hospital effluent also carries antibiotic-resistant bacteria and resistance genes originating from patient excretion. Reducing antibiotic residues alone therefore does not address the full antimicrobial resistance burden present in hospital wastewater.
Must Read: Sustainable Water Use in Dialysis
The contaminant mixture adds further complexity. Transformation products, metabolites, pathogens, PFAS, resistant bacteria and resistance genes can appear alongside pharmaceutical residues. Some treatment processes may also create by-products that retain or increase toxicity. This broader contaminant profile limits the effectiveness of approaches that target only selected compounds.
Operational barriers complicate responses. Routine monitoring remains limited and monitoring windows may underestimate actual emissions. Drug toxicity classifications are not harmonised across EU countries, which restricts comparison and coordinated action. Hospitals also face procurement constraints, limited funding and restricted space for infrastructure. Responsibility for removal is therefore often transferred to municipal wastewater treatment plants, even though these systems were not designed to eliminate the full range of hospital-derived contaminants.
Contrast Agents Highlight Source Interventions
Radiology provides a practical example of targeted emission reduction. Contrast agents represent a persistent class of pharmaceutical pollutants in aquatic environments. Iodine- and gadolinium-based contrast agents are poorly degraded in conventional wastewater treatment and have been detected in sewage, surface water, groundwater and drinking water, particularly near hospitals and imaging facilities. A large proportion of these agents is excreted shortly after administration, creating an opportunity for source-level intervention.
In Milan, radiology departments implemented a simple operational measure. Patients undergoing contrast-enhanced CT or MRI remained in the department for up to 60 minutes after administration so that the first urination could be collected instead of entering the wastewater system. The collected urine was handled outside the standard sewage stream. The intervention relied on workflow changes rather than treatment technology and demonstrated that a significant share of contrast agents can be captured before entering wastewater. Patient acceptance of the waiting period was reported as high.
A pilot project in Mülheim an der Ruhr explored a related approach using urine collection bags. Around 2,000 patients received packs containing four drip-free urine bags over four months, supported by instructions and staff training. The intervention focused on areas served by two hospitals and two radiology practices. Measurements showed reduced concentrations of iodinated contrast media in the effluent of the local wastewater treatment plant, including reductions for specific substances. Estimated costs per examination remained below 10% of overall treatment costs. Such approaches address specific substances and therefore complement broader wastewater management strategies.
Governance, Pre-Treatment and Surveillance Approaches
Discussion increasingly focuses on systemic responses rather than isolated measures. Hospital-level pre-treatment is one proposed approach. Pre-treatment aims to reduce pollutant load before wastewater enters municipal systems while recognising that hospitals cannot function as full wastewater treatment plants. Such interventions may target pharmaceuticals, antimicrobial-resistant bacteria, resistance genes and other hazardous contaminants present at higher concentrations in hospital effluent.
Implementation depends on hospital size, available infrastructure, physical space and investment capacity. Procurement procedures and operational complexity can also slow adoption. Evidence remains limited regarding long-term performance, scalability and cost-effectiveness in real hospital environments.
Innovation initiatives are attempting to address these gaps. The Horizon-funded THERESA pre-commercial procurement programme uses procurement processes to stimulate development of new solutions for hospital wastewater treatment. The initiative defines functional and performance requirements and supports development and testing of technologies in hospital pilot sites across Europe.
Regional governance frameworks are also emerging. In the Central Denmark Region, efforts focus on reducing overall wastewater toxicity in a cost-effective manner rather than targeting individual substances. The model integrates data on pharmaceutical consumption, toxicity and removal rates to prioritise interventions across chemical groups and treatment options. The framework remains under development and requires further validation and improved data comparability.
Wastewater surveillance is gaining attention as a complementary tool. Surveillance can support antimicrobial resistance monitoring, infectious disease preparedness and early warning systems. It can also track pharmaceutical residues and identify emission hotspots or priority hospital departments such as radiology and oncology. Effective implementation requires harmonised monitoring protocols, shared identifiers and stronger coordination between environmental and public health authorities.
Hospital wastewater represents an important source of pharmaceutical pollution and antimicrobial resistance entering aquatic environments. Conventional municipal wastewater treatment systems cannot fully remove pharmaceutical residues, resistant bacteria or resistance genes originating from healthcare facilities. Responses are therefore expanding to include source interventions, hospital-level pre-treatment, governance frameworks and wastewater surveillance. Radiology-based interventions illustrate how operational changes can reduce emissions of persistent substances such as contrast agents. Broader progress will depend on coordinated governance, improved monitoring and adaptable solutions that align environmental protection with healthcare system operations.
Source: Health Care Without Harm
Image Credit: iStock
